Literature DB >> 33536275

Association of High-Density Lipoprotein Cholesterol Variability and the Risk of Developing Parkinson Disease.

Joo-Hyun Park1, Chung-Woo Lee2, Myung Ji Nam2, Hyunjin Kim1, Do-Young Kwon2, Ji Won Yoo2, Kyu Na Lee2, Kyungdo Han1, Jin-Hyung Jung2, Yong-Gyu Park1, Do-Hoon Kim1.   

Abstract

OBJECTIVE: To investigate the longitudinal association among high-density lipoprotein cholesterol (HDL-C) level, HDL-C variability, and the risk of developing Parkinson disease (PD).
METHODS: We conducted a nationwide, population-based cohort study. We included 382,391 patients aged ≥65 years who underwent at least 3 health examinations provided by the Korean National Health Insurance System from 2008 to 2013 and followed up until 2017. Individuals with a history of PD and missing values were excluded (n = 1,987). We assessed HDL-C variability using 3 indices, including variability independent of the mean (VIM). A multivariate-adjusted Cox proportional hazards regression analysis was performed.
RESULTS: Among the 380,404 participants, 2,733 individuals were newly diagnosed with PD during a median follow-up period of 5 years. The lowest quartile (Q1) group of baseline HDL-C and mean HDL-C was associated with increased PD incidence as compared with the highest quartile (Q4) group (adjusted hazard ratio [aHR], 1.20; 95% confidence interval [CI], 1.08-1.34; and aHR, 1.16; 95% CI, 1.04-1.30, respectively). The Q4 group of HDL-C variability (VIM) was associated with increased PD incidence compared to the Q1 group (aHR, 1.19; 95% CI, 1.06-1.33). The group with the Q1 of baseline HDL-C and with the Q4 of HDL-C variability had the highest risk of PD incidence (aHR, 1.6; 95% CI, 1.31-1.96).
CONCLUSION: Lower HDL-C level and greater HDL-C variability were associated with a higher incidence of PD.
© 2021 American Academy of Neurology.

Entities:  

Year:  2021        PMID: 33536275     DOI: 10.1212/WNL.0000000000011553

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

Review 1.  The Endothelium Is Both a Target and a Barrier of HDL's Protective Functions.

Authors:  Jérôme Robert; Elena Osto; Arnold von Eckardstein
Journal:  Cells       Date:  2021-04-28       Impact factor: 6.600

2.  Compared with the monocyte to high-density lipoprotein ratio (MHR) and the neutrophil to lymphocyte ratio (NLR), the neutrophil to high-density lipoprotein ratio (NHR) is more valuable for assessing the inflammatory process in Parkinson's disease.

Authors:  Zhu Liu; Qingli Fan; Shizheng Wu; Yaqi Wan; Yancheng Lei
Journal:  Lipids Health Dis       Date:  2021-04-19       Impact factor: 3.876

3.  Association of serum cholesterol with Parkinson's disease in a cohort of statin-free individuals.

Authors:  Yukai Lv; Bo Xu; Xuejuan Zhang; Chunhuan Chen; Yan Gao; Ning Li
Journal:  Brain Behav       Date:  2021-12-11       Impact factor: 2.708

4.  QEEG indices are associated with inflammatory and metabolic risk factors in Parkinson's disease dementia: An observational study.

Authors:  Hailing Liu; Bin Deng; Hang Zhou; Zhihuan Wu; Yonghua Chen; Guomei Weng; Shuzhen Zhu; Jiangping Xu; Haitao Wang; Zhidong Zhou; Eng-King Tan; Qing Wang
Journal:  EClinicalMedicine       Date:  2022-08-12

5.  Comparison of risk factors for Parkinson's disease, coronary events and ischemic stroke.

Authors:  Lu Song; Shunming Zhang; Huiping Li; Oskar Hansson; Emily Sonestedt; Yan Borné
Journal:  NPJ Parkinsons Dis       Date:  2022-08-25

6.  Biomarker characterization of clinical subtypes of Parkinson Disease.

Authors:  Xiao Deng; Seyed Ehsan Saffari; Nan Liu; Bin Xiao; John Carson Allen; Samuel Yong Ern Ng; Nicole Chia; Yi Jayne Tan; Xinyi Choi; Dede Liana Heng; Yew-Long Lo; Zheyu Xu; Kay-Yaw Tay; Wing-Lok Au; Adeline Ng; Eng-King Tan; Louis C S Tan
Journal:  NPJ Parkinsons Dis       Date:  2022-08-29

Review 7.  Microglial Lipid Biology in the Hypothalamic Regulation of Metabolic Homeostasis.

Authors:  Andrew Folick; Suneil K Koliwad; Martin Valdearcos
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-27       Impact factor: 5.555

Review 8.  Insights into Lewy body disease from rare neurometabolic disorders.

Authors:  Daniel Erskine; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2021-05-30       Impact factor: 3.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.